21 CFR 211.165: Testing and release for distribution
Requires manufacturers to test each drug batch against final specifications, including identity and strength, before release, using written sampling plans and validated methods, and to reject failing batches unless reprocessed to meet standards.
Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals · Subpart I, Laboratory Controls
14%
of drug-manufacturing 483s since 2023 cite this section at least once
How FDA words it
The opening lines investigators use most when they cite 211.165, from the 483s we hold.
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.Most used
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.211.165(b)
The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.211.165(e)
Cited over time
483s citing 211.165, by yearMost citations in 2019. Bars are relative to the busiest year. *2026 to date.
Years shown: 2017 to 2026. The busiest year was 2019.
Recent 483s citing 211.165
- Carolina Infusion, LLC · Ridgeland, South CarolinaYour firm released drug product in which the strength differs from, or its purity… Aug 18, 2026
- Cascade Specialty Pharmacy, LLC · Poulsbo, WashingtonTesting and release of drug product for distribution do not include appropriate… Jul 17, 2026
- Sincerus Florida, LLC dba SKNV · Pompano Beach, FloridaAcceptance criteria for the sampling and testing conducted by the quality control… May 29, 2026
- Wells Pharma of Houston LLC · Houston, TexasDing products failing to meet established specifications and quality control… Apr 13, 2026
- Allure Labs, LLC · Hayward, CaliforniaThe accuracy of test methods have not been established… Mar 27, 2026
The regulation text
§ 211.165 Testing and release for distribution.
(a)For each batch of drug product, there shall be appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Where sterility and/or pyrogen testing are conducted on specific batches of shortlived radiopharmaceuticals, such batches may be released prior to completion of sterility and/or pyrogen testing, provided such testing is completed as soon as possible.
(b)There shall be appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.
(c)Any sampling and testing plans shall be described in written procedures that shall include the method of sampling and the number of units per batch to be tested; such written procedure shall be followed.
(d)Acceptance criteria for the sampling and testing conducted by the quality control unit shall be adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release. The statistical quality control criteria shall include appropriate acceptance levels and/or appropriate rejection levels.
(e)The accuracy, sensitivity, specificity, and reproducibility of test methods employed by the firm shall be established and documented. Such validation and documentation may be accomplished in accordance with § 211.194(a)(2).
(f)Drug products failing to meet established standards or specifications and any other relevant quality control criteria shall be rejected. Reprocessing may be performed. Prior to acceptance and use, reprocessed material must meet appropriate standards, specifications, and any other relevant criteria.
Questions
What does 21 CFR 211.165 require?
Requires manufacturers to test each drug batch against final specifications, including identity and strength, before release, using written sampling plans and validated methods, and to reject failing batches unless reprocessed to meet standards.
How often is 211.165 cited in Form 483s?
It appears in about 14% of the drug-manufacturing 483s we hold from 2023 onward.
How do FDA investigators word a 211.165 observation?
The most common opening is: “Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.”
Which sections are cited alongside 211.165?
In the same 483s, investigators most often also cite 211.192 (Production record review), 211.113 (Control of microbiological contamination), 211.22 (Responsibilities of quality control unit), 211.166 (Stability testing).